赛奇:一个以分段为导向的探索框架,用于优化CDK7抑制剂作为有前途的癌症治疗方法
Zhaoqi Shi1,2, Xufan Gao1, Damiano Buratto1
1Institute of Quantitative Biology, Zhejiang University, Hangzhou 310058, China.
The journal of physical chemistry. B
|August 19, 2025
概括
研究人员开发了针对林依赖激酶7 (CDK7) 的新型非共价抑制剂,用于癌症治疗. 这种计算方法提高了安全性和选择性,为现有的共价CDK7抑制剂提供了有前途的替代方案.
科学领域:
- 药用化学 医学化学
- 计算生物学 计算生物学
- 在瘤学瘤学.
背景情况:
- 循环素依赖酶7 (CDK7) 是细胞循环和转录的关键调节剂,使其成为癌症治疗中的重要标.
- 现有的共价抑制剂THZ1,虽然有效,但有局限性,包括短半衰期和潜在的目标外影响.
研究的目的:
- 设计具有改进的选择性和安全性配置的新型非对应性CDK7抑制剂.
- 通过计算药物设计来解决当前共价CDK7抑制剂的局限性.
主要方法:
- 利用结合虚拟选,分子动力学 (MD) 模拟和自由能量扰动 (FEP) 方法的计算工作流.
- 分析了THZ1的抑制机制,使用MD模拟来识别关键分子碎片.
- 从已知的抑制剂中纳入碎片,在CDK7结合口袋中设计广泛的非共价相互作用.
主要成果:
- 确定了三种新的非共价性CDK7抑制剂.
- 这些新的抑制剂的结合亲和力与THZ1.1的结合亲和力相当或超过.
- 该计算框架成功阐明了THZ1的机制,并指导了改进的抑制剂的设计.
结论:
- 这项研究引入了有前途的非共价CDK7抑制剂作为潜在的癌症治疗药物.
- 开发的计算策略为发现向激酶抑制剂提供了强大的和加速的方法.
- 这项工作为开发更安全,更有效的癌症治疗提供了基础.
更多相关视频
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020
7.4K
06:00Through the Looking Glass: Time-lapse Microscopy and Longitudinal Tracking of Single Cells to Study Anti-cancer Therapeutics
Published on: May 14, 2016
11.1K
相关概念视频
M-Cdk Drives Transition Into Mitosis
5.7K
Checkpoints throughout the cell cycle serve as safeguards and gatekeepers, allowing the cell cycle to progress in favorable conditions and slow or halt it in problematic ones. This regulation is known as the cell cycle control system.
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
Cyclin-dependent kinases, or Cdks, work in concert with cyclins to control cell cycle transitions. M-Cdk, a complex of Cdk1 bound to M cyclin, is a well-known example of this coordinated control that drives the transition from the G2 to the M phase.
M cyclin...
5.7K
Inhibition of Cdk Activity
4.9K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.9K
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Combination Therapies and Personalized Medicine
5.1K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.1K
Adaptive Mechanisms in Cancer Cells
5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Cancer Therapies
7.9K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.9K
